Towards the Future of Next-Generation Pharmaceuticals! How Far Have "Oral GLP-1 Drugs" Progressed? BMF-650 to Announce Results of Initial Clinical Trials

In news about obesity treatment, the percentage of weight loss often catches the eye. However, for those actually undergoing treatment, it's also important whether the treatment can be easily incorporated into daily life, whether the side effects are tolerable, and whether it can be continued long-term.

From this perspective, one of the noteworthy developments is "BMF-650" by the U.S. company Biomea Fusion. It is an orally administered small molecule GLP-1 receptor agonist.

On October 12, 2026, the company announced that it would release the results of its Phase I clinical trial "GLP-131" on the following day, October 13. A conference call and webcast to explain the results are scheduled for 4:30 PM Eastern Time on the 13th, which is 5:30 AM on the 14th in Japan.

However, there is something important to keep in mind when reading this news.This is a pre-announcement of the trial results, not a confirmation of efficacy or safety.

This article is based on information available as of the morning of October 13, Japan time, and organizes the positioning of BMF-650 and points to consider when reading future announcements.

What kind of drug is BMF-650?

GLP-1 is a hormone involved in the regulation of blood sugar and appetite. GLP-1 receptor agonists work by acting on these receptors to elicit effects similar to GLP-1.

BMF-650 is a drug in development that aims to treat obesity using this mechanism. Its characteristic is that it is a "small molecule" intended for oral administration.

For oral GLP-1 drugs, there are methods to facilitate the absorption of peptide-based drugs and methods to design small molecules that aim to be absorbed orally. Even among "oral GLP-1 drugs," the composition and absorption mechanisms of the drugs are not uniform.

Biomea has explained that BMF-650 aims to improve absorption when administered orally and reduce variability in drug concentration within the body.

However, such explanations are based on development goals and previous research.The extent of the benefits when used in humans needs to be confirmed by clinical trial results.

What "Phase I results" mean

Phase I is the initial stage of investigating a new drug in humans.

The main points to confirm are safety, the effects of increasing the dosage, how much of the drug is absorbed into the body, and how long it remains. If possible, preliminary indications of efficacy are also examined.

Regarding BMF-650, the company announced in October 2025 that the first participant had been dosed. The subjects were overweight or obese but otherwise healthy participants, and a plan was presented to evaluate weight changes over 28 days.

If weight loss is confirmed even in a short period, it could provide grounds for further development. However, this alone does not reveal long-term effects or safety when used in a broader range of patients.

For example, there may be side effects that are not apparent in trials lasting only a few weeks. Further verification is needed to determine how weight changes with continued treatment and whether it can be used similarly in people with complications.

Phase I is an important step in assessing the potential of a new drug, but it does not guarantee approval or widespread use.

It's not just about "how much weight was lost" in the announcement

When results are announced, the weight loss rate is likely to catch the eye first. However, the meaning of the numbers varies depending on the trial conditions.

When reading, at least the following points should be checked.

• How many people participated, and how many were in each dosage group.
• How long the drug was administered and when the weight was measured.
• How much difference there was compared to the placebo group.
• How those who discontinued the treatment midway were handled in the analysis.
• The extent of adverse events, their severity, and reasons for discontinuation.

This does not imply that there is a problem with BMF-650. For any new drug, these are perspectives to verify aspects that cannot be seen from average values alone.

Caution is also needed when comparing short-term trial results with those of other drugs over several weeks. If the subjects, dosage, lifestyle interventions, and analysis methods differ, superiority cannot be determined by numbers alone.

This announcement does not include such specific results. Therefore, at this stage, there is insufficient material to evaluate it as "superior to existing drugs" or "having fewer side effects."

Will side effects be lighter if it becomes an oral medication?

For those who wish to avoid injections, oral medications can be an attractive option. However, just because it becomes an oral medication does not mean that the side effects associated with the drug's action will disappear.

In the evaluation of oral semaglutide preparations published by the European Medicines Agency in May 2026, gastrointestinal symptoms such as nausea, diarrhea, constipation, abdominal pain, and vomiting were listed as the main side effects, and the safety profile was described as similar to that of the once-weekly injection formulation.

This is information about a different drug and does not imply that BMF-650 will have the same frequency of side effects. However, it indicates that one cannot judge the burden on the body solely based on the method of administration, thinking "because it's an oral drug, the burden is smaller."

The same applies to ease of use. Oral medications may have conditions such as intervals with meals. For example, patient materials for Rybelsus in Japan explain that it should be taken on an empty stomach and that eating or drinking should be avoided for at least 30 minutes after taking it.

It cannot be assumed what the final dosing conditions for BMF-650 will be based on other oral medications. In addition to efficacy and side effects, whether it is a dosing method that can be maintained in daily life will also be a point of evaluation in the future.

Interest in efficacy and usability on social media—distinguishing reactions to BMF-650

The general user reactions specific to BMF-650 regarding this announcement could not be fully grasped based on the available public information. It cannot be evaluated as "expectations are flooding on social media."

On the other hand, discussions comparing oral GLP-1 drugs and injectable drugs can be seen on overseas forums like Reddit.

Posts that could be confirmed included content considering oral drugs as relatively mild in effect and as an option. Conversely, there were opinions that a once-weekly injection is preferable, and voices emphasizing the importance of insurance-covered options.

What can be inferred from this is that users' interest is not solely focused on weight loss effects. The frequency of administration and cost burden are also factors in choosing a drug.

However, these are limited individual posts and do not represent the opinions of all patients. They are not impressions of using BMF-650.

Additionally, simple generalizations such as oral drugs being weaker or stronger than injectable drugs cannot be made. While social media can provide clues to everyday questions, clinical data for each formulation is necessary to assess the efficacy and safety of drugs.

Three things Japanese readers should not confuse

When reading this news in Japan, it's important to distinguish between "progress in clinical trials," "drug approval," and "actual availability for use."

Even if initial trial results are released overseas, it does not mean approval or the start of prescriptions in Japan. The current announcement does not include information on the release date, price, or insurance coverage in Japan.

Furthermore, even among GLP-1-related drugs, the diseases they are approved for and the target individuals vary by formulation. News about new drugs should not be a reason to change current treatment based on self-judgment.

The value that BMF-650 should demonstrate in the future is not just its oral administration. It should be a treatment with sufficient efficacy, balanced side effects, and ease of continuation for those who need it.

In the result announcement, attention should be paid not only to the eye-catching weight loss rate but also to the trial conditions and safety information that support those numbers.

Sources and References

1. Aktiencheck
   Announcement of the Phase I trial results for BMF-650. Company announcement distributed by GlobeNewswire.
   https://www.aktiencheck.de/news/Artikel-Biomea_Fusion_to_Announce_Phase_I_Results_for_BMF_650_Its_Next_Generation_Oral_Small_Molecule_GLP_1_Receptor_Agonist-20164591

2. Biomea Fusion's announcement on October 12, 2026 / GlobeNewswire
   Primary source confirming the date of the GLP-131 trial results announcement and the time of the briefing. The announcement text does not include specific trial results.
   https://www.globenewswire.com/news-release/2026/10/12/3379251/0/en/biomea-fusion-to-announce-phase-i-results-for-bmf-650-its-next-generation-oral-small-molecule-glp-1-receptor-agonist.htmlglobenewswire.com

3. Biomea Fusion's announcement on October 27, 2025
   Materials on the initial dosing of BMF-650, its developmental characteristics, trial subjects, and plans to evaluate weight changes over 28 days.
   https://investors.biomeafusion.com/news-releases/news-release-details/biomea-fusion-announces-first-patient-dosed-phase-i-study-bmfBiomea Fusion

4. U.S. FDA "Drug Development and Review Definitions"
   Official explanation of the purposes from Phase I to Phase III and the stages of new drug evaluation.
   https://www.fda.gov/drugs/investigational-new-drug-application-ind/drug-development-and-review-definitionsFDA

5. European Medicines Agency "First oral GLP-1 treatment for weight management"
   Official materials on the dosing conditions, trial results, and gastrointestinal symptoms as the main side effects of oral semaglutide. Information on a different formulation than BMF-650.
   https://www.ema.europa.eu/en/news/first-oral-glp-1-treatment-weight-managementEuropean Medicines Agency (EMA)

6. PMDA "Rybelsus Tablets Patient Guide"
   Materials explaining the dosing conditions for oral GLP-1 formulations in Japan.
   https://www.info.pmda.go.jp/downfiles/guide/ph/620023_2499014F1021_1_00G.pdfinfo.pmda.go.jp

7. Reddit "Glp injection or oral medicine"
   Posts discussing the perception of effects and available options for oral and injectable drugs. Referenced as individual opinions on social media, not used as medical evidence.
   https://www.reddit.com/r/GLP1ResearchTalk/comments/1vcuqp7/glp_injection_or_oral_medicine/